arBtrage CAPITALIZING MARKETS — checking… Sign in Sign up
Calendar /

Krystal Biotech, Inc.

KRYS Health Care Biotechnology: Biological Products (No Diagnostic Substances)
$358.24
Today
as of Sep 4, 16:51 ET
Last 30 days -1.64% Jul 28 → Sep 04
$307.86 $324.94 $342.02 $359.10 $376.18 Jul 28 Aug 05 Aug 12 Aug 20 Aug 27 Sep 04
Open
$365.45
High
$371.99
Low
$353.75
Volume
$319,765
Avg Vol
$329,442
Mkt Cap
$9.7B
P/E (TTM)
57.04
Beta
—
52w High
$382.54
52w Low
$136.73
Div Yield
—
Shares Out
$30M

Recent Press Releases & News last 60 days · 21 items

Sep 3 · 15:49 Zacks
Krystal Stock Gains 13.4% in a Month: What Is Driving the Rally?
Sep 3 · 12:00 PR GlobeNewswire
Krystal Biotech to Present at 2026 Cantor Global Healthcare Conference
Sep 2 · 15:30 Zacks
Krystal Biotech (KRYS) Up 12% Since Last Earnings Report: Can It Continue?
▸ Show all 21 press releases & news Free account →

Overview

52-week range
$137
$383
90% of range
Avg surprise (last 3)
+10.9%
Avg reaction (last 2)
-3.1%
50% positive
Latest IV / EM
40%
EM ±6.2% · $360 · Sep 18

Earnings trends

EPS — actual vs estimate Actual Estimate
$-1.76$-0.62$0.51$1.65$2.79 Actual $-1.76Actual $-1.25Actual $2.79Actual $0.03Actual $0.53Actual $0.91Actual $1.20Est $1.38Actual $1.29Est $1.08Actual $2.66Actual $1.83Est $1.45Actual $1.79 MarJunSepMarJunSepMar/2025Jun/2025SepMar/2026Jun
Revenue vs Net Income Revenue Net income
$0$31M$63M$94M$125M Sep 24Mar 25Jun 25Sep 25Mar 26Jun 26

Earnings history

DatePeriodActual EPSEstSurpriseYoY %ΔDay reactSource
Tue Jun 30, 2026Jun 2026 $1.79 — — — — financials
Mon May 4, 2026Mar/2026 $1.83 $1.45 +26.2% +52.5% +7.9% earnings
Tue Sep 30, 2025Sep 2025 $2.66 — — — — financials
Mon Aug 4, 2025Jun/2025 $1.29 $1.08 +19.4% — — earnings
Tue May 6, 2025Mar/2025 $1.20 $1.38 -13.0% — -14.1% earnings
Mon Sep 30, 2024Sep 2024 $0.91 — — — — financials
Sun Jun 30, 2024Jun 2024 $0.53 — — — — financials
Sun Mar 31, 2024Mar 2024 $0.03 — — — — financials
Sat Sep 30, 2023Sep 2023 $2.79 — — — — financials
Fri Jun 30, 2023Jun 2023 $-1.25 — — — — financials
Fri Mar 31, 2023Mar 2023 $-1.76 — — — — financials

Financials

Income statement (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue$119M$116M—$98M$96M$88M—$84M
Cost of revenue————————
Gross profit————————
Operating income$58M$54M—$41M$39M$36M—$22M
Net income$55M$56M—$79M$38M$36M—$27M
EPS (diluted)$1.79$1.83—$2.66$1.29$1.20—$0.91

Balance sheet (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Cash & equivalents$428M$501M$496M$393M$354M$309M$345M$374M
Inventory$46M$43M$40M$38M$31M$30M$27M$19M
Total current assets$1.06B$1.02B$1.02B$926M$841M$767M$742M$713M
Total assets$1.50B$1.40B$1.33B$1.24B$1.14B$1.07B$1.06B$982M
Long-term debt————————
Total liabilities$142M$120M$114M$102M$98M$90M$109M$96M
Total equity$1.36B$1.28B$1.22B$1.14B$1.04B$985M$946M$886M

Implied volatility — last 90 days

36%43%50%58%65% Jun 07 — IV 45% · EM ±6.2%Jun 08 — IV 43% · EM ±5.7%Jun 09 — IV 43% · EM ±5.4%Jun 10 — IV 44% · EM ±5.2%Jun 11 — IV 45% · EM ±5.0%Jun 12 — IV 41% · EM ±4.2%Jun 15 — IV 51% · EM ±3.7%Jun 16 — IV 53% · EM ±3.2%Jun 17 — IV 56% · EM ±2.3%Jun 19 — IV 39% · EM ±8.6%Jun 22 — IV 41% · EM ±8.5%Jun 23 — IV 40% · EM ±8.3%Jun 24 — IV 40% · EM ±7.9%Jun 25 — IV 41% · EM ±7.9%Jun 26 — IV 40% · EM ±7.6%Jun 29 — IV 42% · EM ±7.4%Jun 30 — IV 41% · EM ±7.1%Jul 01 — IV 41% · EM ±6.9%Jul 02 — IV 38% · EM ±6.2%Jul 03 — IV 40% · EM ±6.2%Jul 06 — IV 45% · EM ±6.2%Jul 07 — IV 44% · EM ±5.8%Jul 08 — IV 45% · EM ±5.6%Jul 09 — IV 42% · EM ±5.0%Jul 10 — IV 41% · EM ±4.6%Jul 13 — IV 47% · EM ±3.9%Jul 14 — IV 54% · EM ±3.9%Jul 15 — IV 49% · EM ±2.9%Jul 16 — IV 55% · EM ±2.3%Jul 20 — IV 52% · EM ±12.4%Jul 21 — IV 55% · EM ±12.7%Jul 22 — IV 53% · EM ±12.1%Jul 23 — IV 53% · EM ±12.0%Jul 24 — IV 54% · EM ±11.8%Jul 27 — IV 61% · EM ±12.8%Jul 28 — IV 60% · EM ±12.3%Jul 29 — IV 61% · EM ±12.3%Jul 30 — IV 62% · EM ±12.2%Jul 31 — IV 65% · EM ±12.5%Aug 03 — IV 47% · EM ±8.3%Aug 04 — IV 46% · EM ±7.9%Aug 05 — IV 44% · EM ±7.4%Aug 06 — IV 42% · EM ±6.9%Aug 07 — IV 40% · EM ±6.3%Aug 10 — IV 40% · EM ±5.5%Aug 11 — IV 40% · EM ±5.3%Aug 12 — IV 38% · EM ±4.7%Aug 13 — IV 39% · EM ±4.6%Aug 14 — IV 37% · EM ±4.1%Aug 17 — IV 45% · EM ±3.8%Aug 18 — IV 47% · EM ±3.4%Aug 19 — IV 52% · EM ±3.0%Aug 20 — IV 56% · EM ±2.4%Aug 24 — IV 38% · EM ±7.9%Aug 25 — IV 39% · EM ±8.1%Aug 26 — IV 40% · EM ±8.1%Aug 27 — IV 38% · EM ±7.5%Aug 28 — IV 39% · EM ±7.6%Aug 31 — IV 42% · EM ±7.4%Sep 01 — IV 42% · EM ±7.2%Sep 02 — IV 40% · EM ±6.6%Sep 03 — IV 40% · EM ±6.4%Sep 04 — IV 40% · EM ±6.2%

Sector peers

LLY
Eli Lilly and Company
$1.1T $1,148.00-0.1%
JNJ
Johnson & Johnson
$671.0B $275.71+0.2%
ABBV
AbbVie Inc.
$430.9B $256.50+0.1%
MRK
Merck & Company, Inc.
$317.1B $150.33+0.0%
PM
Philip Morris International Inc
$299.3B $182.53+0.0%
NVS
Novartis AG
$297.9B $155.11-3.0%
View on Nasdaq ↗
🔒 Preview mode. Create a free account to unlock the full earnings calendar, all panels, heatmaps, options flow, and screener.
Sign up free → Sign in